New hope for liver cancer patients: drug combo trial launches
NCT ID NCT07493668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the experimental drug fostrox to the standard drug lenvatinib helps shrink tumors or slow cancer growth in people with advanced liver cancer. About 80 adults whose cancer worsened after initial immunotherapy will be randomly assigned to receive either the combo or lenvatinib alone. The main goal is to see how many patients have their tumors shrink significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHA Bundang Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple therapy shrink untreatable liver tumors?
- Breath of life: new test could sniff out gut cancers before they spread
- Immune cell therapy takes on untreatable liver cancer
- Could your own immune cells keep liver cancer from coming back?
- New ultrasound technique could reveal hidden blood vessels in liver tumors
- New imaging tracer could spot hidden cancers and fibrosis in one scan